This Article Abstract Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Fernandes, L. S. Search for Related Content PubMed PubMed Citation Articles by Fernandes, L. S.

Is glycoprotein IIb/IIIa antagonism as effective in women as in men following percutaneous coronary intervention?

Lessons from the ESPRIT study

Laura S. Fernandes, MD^*, James E. Tcheng, MD, FACC, J. Conor O’Shea, MD, Bonnie Weiner, MD, FACC, Todd J. Lorenz, MD, Cindy Pacchiana, MS, Lisa G. Berdan, PA-C, Kelly J. Maresh, RN^*, Diane Joseph, BS, Mina Madan, MD^||, Tift Mann, MD, FACC^¶, Rakhi Kilaru, MS, Judith S. Hochman, MD, FACC^**, Neal S. Kleiman, MD, FACC^*,* ESPRIT Investigators

^* Baylor College of Medicine and the Methodist DeBakey Heart Center, Houston Texas, USA
Duke Clinical Research Institute, Durham, North Carolina, USA
University of Massachusetts, Worcester, Massachusetts, USA
COR Therapeutics, South San Francisco, California, USA
^|| Sunnybrook and Women’s College Health Sciences Centre, Toronto, Ontario, Canada
^¶ Wake Heart Associates, Raleigh, North Carolina, USA
^** Columbia University and St. Luke’s Roosevelt Hospital, New York, New York, USA

View larger version (20K): [in a new window]   Figure 1 Individual selected elements of the composite end point at 48 h for men and women. MI = myocardial infarction; uTVR = urgent target vessel revascularization.

View larger version (21K): [in a new window]   Figure 2 Kaplan-Meier estimates of the composite of death, myocardial infarction, or target vessel revascularization during the first year, according to gender and treatment with eptifibatide.

View larger version (19K): [in a new window]   Figure 3 Kaplan-Meier estimates of death or myocardial infarction during the first year according to gender and eptifibatide treatment.